



Evaluation of the Impact of a Clinical Pharmacist-Led Patient Engagement Program on Cost Savings

Charles Worrall, PharmD Candidate¹, Jeff Bullard, MD², David Shirley, PharmD¹, Angela Shaw Kuo, PharmD², Anthony DeClue, PharmD, MA, BCACP, CDCES¹, Taylor Morrisette, PharmD, MPH^{1,3}

¹Department of Clinical Pharmacy and Outcomes Sciences, Medical University of South Carolina College of Pharmacy, Charleston, SC, USA, ²Stellus Rx, Plano, TX, USA, ³Department of Pharmacy Services, Medical University of South Carolina Health, Charleston, SC, USA

Background


- Chronic conditions affect 60% of adults within the United States with approximately half of these patients classified as being non-adherent to their medication regimens.^{1,2}
- Importantly, medication non-adherence contributes up to an estimated \$300 billion annually in avoidable health care costs.³
- Studies have shown that medication adherence, health outcomes, and healthcare costs can be improved through clinical pharmacist-led engagement.⁴
- This clinical pharmacy-driven network focuses on patient engagement in those with chronic diseases and provides patient-centered care using clinical workflow and data management systems.
- The service's goal is to increase medication adherence, improve health outcomes, and reduce healthcare expenditures through individual case review and pharmacist-led patient outreach by supporting change and empowerment.
- The primary objective of this study is to evaluate potential medical expense cost savings associated with this clinical pharmacist-led patient engagement program.

Methods

- This is a multicenter, retrospective, quasiexperimental evaluation of patients pre- and postenrollment into this clinical pharmacist-led patient engagement program.
- This program provides personalized medication optimization, medication education, behavioral modifications, and can also align medication delivery at patients' requests with a minimum of oncemonthly live appointments and two digital clinical assessments per quarter (**figure 1**).
- Baseline per member per month (PMPM) medical costs had been calculated over the 12-month period prior to enrollment and over at least a 9-month period following enrollment.
- Patients with total medical expenses exceeding \$120,000 in either the pre- or post-enrollment 12month period were excluded.
- The primary outcome is medical expense cost savings PMPM for patients enrolled in this engagement program.
- Secondary objectives include identifying those patients who may benefit most from program enrollment.
- Descriptive statistics were utilized for analysis.

Service or Program

Figure 1: General Process of the Pharmacist-Led Medication Engagement Program



Results

Table 1: Pharmacist-Led Medication Engagement Program: Medical Expense Cost Savings






Figure 2: Predictive Indicators and Key Criteria for Evaluating Patients' Needs for Medication Engagement




Results

Figure 3: Demonstration of Patient Impact














- 868 Medicare Advantage patients were enrolled.
- There was a medical cost savings of \$113.60 PMPM (\$1,363.20 per member per year) for patients of whom were enrolled in the program for at least nine months (**Table 1**).
- Patients who received the greatest benefit from the program are shown in **figure 2**.

Conclusions

- This clinical pharmacist-led patient engagement program was shown to reduce medical spend in over 850 Medicare Advantage patients.
- Further research should evaluate the impact of this clinical pharmacist-led service on clinical outcomes.

References

- 1. Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion. Chronic diseases in America. Reviewed: October 4, 2024. Accessed: March 8, 2025. https://www.cdc.gov/chronicdisease/resources/infographic/chronic-diseases.htm.
- 2. Kleinsinger F. The unmet challenge of medication nonadherence. *Perm J.* 2018;22:18-033.
- 3. Benjamin RM. Medication adherence: helping patients take their medicines as directed. *Public Health Rep.* 2012;127(1):2-3.
- 4. Elnaem MH, Rosley NFF, Alhifany AA, Elrggal ME, Cheema E. Impact of pharmacist-led inteventions on medication adherence and clinical outcomes in patients with hypertension and hyperlipidemia: a scoping review of published literature. *J Multidiscip Healthc*. 2020;13:635-45.

Disclosures

This study was funded by Stellus Rx. TM is currently receiving grant funding from Stellus Rx and AbbVie, Inc., has participated in scientific advisory boards for AbbVie, Inc. and Basilea Pharmaceutica, has provided expert witness testimony to Copeland Stair Valz & Lovell, and has received honorarium from Infectious Diseases Special Edition and Managed Healthcare Executive. JB and ASK are current employees of Stellus Rx. CW, DS, and AD have no conflicts of interest to disclose.